First, while we proposed that combining high-dose HFSRT with dual immunotherapy (ipilimumab and nivolumab) and a VEGF inhibitor (bevacizumab) may enhance immunological responses on the basis of preclinical models in gliomas, we lacked sufficient tumoral tissue or serum biomarkers during treatment to sufficiently answer this question in our trial. The gene discussed is VEGFA; the disease is central nervous system cancer.